This study uses explainable AI to extract gait features that differentiate Parkinson's disease and indicate sensitivity to deep brain stimulation.

Explainable, DBS-responsive gait biomarkers offer translational value for patient selection and objective monitoring of therapeutic response, but the work is clinical/phenotypic and lacks molecular or mechanistic targets for drug discovery.